🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 15 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
02/02/2024 25,47 25,85 24,79 25,18 -3,27% 4,14% 745.400
01/02/2024 26,24 26,34 25,22 26,03 -0,23% 4,27% 760.600
31/01/2024 26,52 27,35 26,02 26,09 -1,77% 5,03% 940.400
30/01/2024 28,13 28,13 26,44 26,56 -5,68% 6,01% 902.600
29/01/2024 27,13 28,50 25,79 28,16 +4,10% 9,99% 928.500
26/01/2024 25,71 27,21 25,10 27,05 +1,46% 8,21% 2.864.600
25/01/2024 27,23 28,09 26,53 26,66 -2,02% 5,73% 1.052.300
24/01/2024 28,36 28,65 27,18 27,21 -2,68% 5,18% 562.500
23/01/2024 27,79 28,19 27,33 27,96 +2,53% 3,09% 667.900
22/01/2024 27,29 27,91 27,00 27,27 +0,78% 3,33% 1.105.400
19/01/2024 27,37 27,57 26,16 27,06 -0,99% 5,15% 4.177.600
18/01/2024 27,99 28,35 27,00 27,33 -2,74% 4,82% 1.110.900
17/01/2024 28,50 28,81 27,16 28,10 -1,82% 5,79% 887.100
16/01/2024 27,13 28,73 26,99 28,62 +4,72% 6,40% 1.192.800
12/01/2024 29,23 29,55 27,15 27,33 -5,01% 8,21% 762.600
11/01/2024 28,45 29,03 27,96 28,77 -0,28% 3,76% 1.197.500
10/01/2024 28,51 29,36 27,90 28,85 +0,49% 5,12% 912.800
09/01/2024 29,32 30,00 28,57 28,71 -4,27% 4,88% 1.330.300
08/01/2024 27,81 30,00 27,07 29,99 +7,49% 10,54% 1.384.900
05/01/2024 27,50 27,98 26,86 27,90 -0,68% 4,07% 849.200
04/01/2024 27,44 28,33 27,44 28,09 +3,16% 3,24% 1.269.200
03/01/2024 27,68 27,94 27,00 27,23 -2,89% 3,40% 1.019.500
02/01/2024 27,04 28,49 27,00 28,04 +1,74% 5,51% 976.800
29/12/2023 28,53 28,53 27,26 27,56 -3,57% 4,47% 1.216.500
28/12/2023 29,17 29,35 28,07 28,58 -2,69% 4,39% 868.800
27/12/2023 28,54 29,41 28,19 29,37 +3,09% 4,27% 797.700
26/12/2023 28,02 28,89 27,91 28,49 +3,19% 3,50% 671.400
22/12/2023 28,64 29,23 27,54 27,61 -2,85% 5,90% 923.200
21/12/2023 27,64 28,73 27,64 28,42 +5,10% 3,94% 1.083.100
20/12/2023 27,59 28,30 26,95 27,04 -2,03% 4,87% 1.148.400